Similar articles

• Role of lipid and lipoprotein profiles in risk assessment and therapy.

  Ballantyne CM, Hoogeveen RC. Ballantyne CM, et al. Am Heart J. 2003 Aug;146(2):227-33. doi: 10.1016/S0002-8703(02)94701-0. Am Heart J. 2003. PMID: 12891189 Review.
• Relative contribution of lipids and apolipoproteins to incident coronary heart disease and ischemic stroke: the PRIME Study.

  Canouï-Poitrine F, Luc G, Bard JM, Ferrieres J, Yarnell J, Arveiler D, Morange P, Kee F, Evans A, Amouyel P, Ducimetiere P, Empana JP; PRIME Study Group. Canouï-Poitrine F, et al. Cerebrovasc Dis. 2010 Aug;30(3):252-9. doi: 10.1159/000319067. Epub 2010 Jul 23. Cerebrovasc Dis. 2010. PMID: 20664258
• [Lipid determination in current medical practice].

  Bakir R, Chanu B, Rouffy J. Bakir R, et al. Ann Dermatol Venereol. 1986;113(9):855-9. Ann Dermatol Venereol. 1986. PMID: 3827091 French. No abstract available.
• Triglycerides and coronary artery disease.

  Sum CF, Tan CE, Wang KW. Sum CF, et al. Singapore Med J. 1992 Oct;33(5):443-5. Singapore Med J. 1992. PMID: 1455264 No abstract available.
• Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease.

  Onat A. Onat A. Anadolu Kardiyol Derg. 2004 Sep;4(3):236-45. Anadolu Kardiyol Derg. 2004. PMID: 15355827 Review.